How convenient

Johnson & Johnson to Acquire $2 Billion Drug Developer “Ambrx Biopharma” to Treat Turbo Cancers with Same Tech as Pfizer’s $43 Billion Seagen Acquisition

https://www.globalresearch.ca/johnson-johnson-acquire-2-billion-drug-developer-ambrx-biopharma-treat-turbo-cancers-same-tech-pfizer-43-billion-seagen-acquisition/5846611